ImmuPharma Selling And Marketing Expenses from 2010 to 2024

IMM Stock   1.16  0.04  3.57%   
ImmuPharma PLC's Selling And Marketing Expenses is decreasing over the years with slightly volatile fluctuation. Selling And Marketing Expenses is expected to dwindle to about 112.2 K. During the period from 2010 to 2024 ImmuPharma PLC Selling And Marketing Expenses annual values regression line had geometric mean of  137,200 and mean square error of 45 M. View All Fundamentals
 
Selling And Marketing Expenses  
First Reported
2013-09-30
Previous Quarter
16.3 K
Current Value
16.3 K
Quarterly Volatility
425.5 K
 
Yuan Drop
 
Covid
Check ImmuPharma PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmuPharma PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 35.7 K, Interest Expense of 1.9 K or Selling General Administrative of 1.7 M, as well as many indicators such as . ImmuPharma financial statements analysis is a perfect complement when working with ImmuPharma PLC Valuation or Volatility modules.
  
This module can also supplement various ImmuPharma PLC Technical models . Check out the analysis of ImmuPharma PLC Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in ImmuPharma Stock

ImmuPharma PLC financial ratios help investors to determine whether ImmuPharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImmuPharma with respect to the benefits of owning ImmuPharma PLC security.